Hutchmed's hope for adults with primary immune thrombocytopenia

Commercial-stage biopharma company, Hutchmed, has good news for adults with primary immune thrombocytopenia (ITP).

Related Keywords

China ,Weiguo Su ,China National Medical Products Administration ,Lancet Haematology ,Breakthrough Therapy ,Clinical Development ,Drug Delivery ,Ingredients ,Markets Amp Regulations ,Atient Centricity ,Pis Active Pharmaceutical Ingredients ,Regulations ,Phase Iii Iv ,Hutchmed ,Research ,Clinical Trials ,Fda ,Tampa ,